Literature DB >> 11445638

Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.

Y K Hayashi1, M Ogawa, K Tagawa, S Noguchi, T Ishihara, I Nonaka, K Arahata.   

Abstract

BACKGROUND: Fukuyama-type congenital muscular dystrophy (FCMD) is an autosomal recessive disorder characterized by severe dystrophic muscle wasting from birth or early infancy with structural brain abnormalities. The gene for FCMD is located on chromosome 9q31, and encodes a novel protein named fukutin. The function of fukutin is not known yet, but is suggested to be an enzyme that modifies the cell-surface glycoprotein or glycolipids.
OBJECTIVE: To elucidate the roles of fukutin gene mutation in skeletal and cardiac muscles and brain.
METHODS: Immunohistochemical and immunoblot analyses were performed in skeletal and cardiac muscles and brain tissue samples from patients with FCMD and control subjects.
RESULTS: The authors found a selective deficiency of highly glycosylated alpha-dystroglycan, but not beta-dystroglycan, on the surface membrane of skeletal and cardiac muscle fibers in patients with FCMD. Immunoblot analyses also showed no immunoreactive band for alpha-dystroglycan, but were positive for beta-dystroglycan in FCMD in skeletal and cardiac muscles.
CONCLUSION: The current findings suggest a critical role for fukutin gene mutation in the loss or modification of glycosylation of the extracellular peripheral membrane protein, alpha-dystroglycan, which may cause a crucial disruption of the transmembranous molecular linkage of muscle fibers in patients with FCMD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445638     DOI: 10.1212/wnl.57.1.115

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  44 in total

1.  Muscular dystrophy: A hidden ancestral legacy trumped.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

Review 2.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

3.  A role of fukutin, a gene responsible for Fukuyama type congenital muscular dystrophy, in cancer cells: a possible role to suppress cell proliferation.

Authors:  Tomoko Yamamoto; Yoichiro Kato; Noriyuki Shibata; Tatsuo Sawada; Makiko Osawa; Makio Kobayashi
Journal:  Int J Exp Pathol       Date:  2008-10       Impact factor: 1.925

4.  Post-transcriptional regulation of fukutin in an astrocytoma cell line.

Authors:  Tomoko Yamamoto; Yoichiro Kato; Atsuko Hiroi; Noriyuki Shibata; Makiko Osawa; Makio Kobayashi
Journal:  Int J Exp Pathol       Date:  2012-02       Impact factor: 1.925

Review 5.  Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage.

Authors:  Paul T Martin
Journal:  Nat Clin Pract Neurol       Date:  2006-04

Review 6.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

7.  Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality.

Authors:  Tobias Willer; Belén Prados; Juan Manuel Falcón-Pérez; Ingrid Renner-Müller; Gerhard K H Przemeck; Mark Lommel; Antonio Coloma; M Carmen Valero; Martin Hrabé de Angelis; Widmar Tanner; Eckhard Wolf; Sabine Strahl; Jesús Cruces
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

8.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

9.  Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.

Authors:  Alison K Esser; Michael R Miller; Qin Huang; Melissa M Meier; Daniel Beltran-Valero de Bernabé; Christopher S Stipp; Kevin P Campbell; Charles F Lynch; Brian J Smith; Michael B Cohen; Michael D Henry
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

10.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.